Alterity Therapeutics Limited

ATH

AU0000043945

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-06-03 am EDT			5-day change	1st Jan Change
0.005 ^AUD	0.00%		0.00%	-28.57%

May. 08	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	CI
May. 08	Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	MT

Alterity Therapeutics Limited Announces the Cessation of George Mihaly as Director, Effective 8 April 2019

April 10, 2019 at 07:08 pm EDT

Alterity Therapeutics Limited announced the cessation of Dr. George Mihaly as director, effective 8 April 2019.

Latest news about Alterity Therapeutics Limited

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	May. 08	CI
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	May. 07	MT
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	Apr. 29	CI
ADRs End Lower, Purple Biotech Ltd. Declines 29%	Apr. 16	DJ
ADRs End Lower, Leju Holdings Ltd. Declines 72%	Apr. 12	DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	Apr. 11	DJ
ADRs Close Lower; VIA Optronics AG Declines 30%	Apr. 10	DJ
Top Midday Gainers	Apr. 10	MT
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	Mar. 25	MT
Genetic Technologies Appoints CFO	Mar. 25	MT
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	Feb. 28	CI
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	Feb. 22	MT
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	Feb. 06	CI
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation	Feb. 06	MT
Alterity Therapeutics Completes Securities Purchase Plan	Feb. 01	MT
Alterity Dispatches Documents Of Planned Share Sale	Jan. 10	MT
Alterity Therapeutics Concludes Second Tranche of Placement of AU$3.5 Million; Shares Plunge 20%	Jan. 07	MT
Alterity Therapeutics to Raise Up to AU$2 Million Via Share Purchase Plan	Dec. 29	MT
Transcript : Alterity Therapeutics Limited - Shareholder/Analyst Call	Dec. 28
Alterity Therapeutics Names Phillip Hains as Chief Financial Officer	Dec. 21	MT
Alterity Therapeutics Limited Announces CFO Changes	Dec. 21	CI
ADRs End Lower; Evaxion Biotech Declines 27%	Dec. 05	DJ
Transcript : Alterity Therapeutics Limited - Special Call	Dec. 05
Top Premarket Decliners	Dec. 05	MT

Chart Alterity Therapeutics Limited

Duration

Period

More charts

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Sector

Biotechnology & Medical Research

Calendar

2025-02-26 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALTERITY THERAPEUTICS LIMITED	-28.57%	17.41M
MODERNA, INC.	+45.54%	54.63B
IQVIA HOLDINGS INC.	-6.91%	39.92B
LONZA GROUP AG	+37.07%	38.82B
ICON PUBLIC LIMITED COMPANY	+13.00%	26.86B
CELLTRION, INC.	-11.17%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.08%	18.78B
UNITED THERAPEUTICS CORPORATION	+24.87%	12.21B
BIO-TECHNE CORPORATION	+0.09%	12.16B
MEDPACE HOLDINGS, INC.	+25.11%	11.94B

Other Biotechnology & Medical Research